Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records
CNS Drugs · 2023-09 · 37 (9) · 819-835
DOI: 10.1007/s40263-023-01033-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 09.09.2023. Verfasst von Vicente Villanueva und 17 weiteren Autor:innen. Beteiligte Einrichtung: Refractory Epilepsy Unit, Hospital Universitario y Politécnico La Fe, EpiCARE member, Avenida Fernando Abril Martorell 106, 46026, Valencia, Spain. v…. Hauptthemen laut MEDLINE: Pyrrolidinones. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Real-world evidence studies of brivaracetam (BRV) have been restricted in scope, location, and patient numbers. The objective of this pooled analysis was to assess effectiveness and tolerability of brivaracetam (BRV) in routine practice in a large international population. METHODS: EXPERIENCE/EPD332 was a pooled analysis of individual patient records from multiple independent non-interventional studies of patients with epilepsy initiating BRV in Australia, Europe, and the United States. Eligible study cohorts were identified via a literature review and engagement with country lead investigators, clinical experts, and local UCB Pharma scientific/medical teams. Included patients initiated BRV no earlier than January 2016 and no later than December 2019, and had ≥ 6 months of follow-up data. The databases for each cohort were reformatted and standardised to ensure information collected was consistent. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within 3 months before timepoint), continuous seizure freedom (no seizures from baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Patients with missing data after BRV discontinuation were considered non-responders/not seizure free. Analyses were performed for all adult patients (≥ 16 years), and for subgroups by seizure type recorded at baseline; by number of prior antiseizure medications (ASMs) at index; by use of BRV as monotherapy versus polytherapy at index; for patients who switched from levetiracetam to BRV versus patients who switched from other ASMs to BRV; and for patients with focal-onset seizures and a BRV dose of ≤ 200 mg/day used as add-on at index. Analysis populations included the full analysis set (FAS; all patients who received at least one BRV dose and had seizure type and age documented at baseline) and the modified FAS (all FAS patients who had at least one seizure recorded during baseline). The FAS was used for all outcomes other than ≥ 50% seizure reduction. All outcomes were summarised using descriptive statistics. RESULTS: Analyses included 1644 adults. At baseline, 72.0% were 16-49 years of age and 92.2% had focal-onset seizures. Patients had a median (Q1, Q3) of 5.0 (2.0, 8.0) prior antiseizure medications at index. At 3, 6, and 12 months, respectively, ≥ 50% seizure reduction was achieved by 32.1% (n = 619), 36.7% (n = 867), and 36.9% (n = 822) of patients; seizure freedom rates were 22.4% (n = 923), 17.9% (n = 1165), and 14.9% (n = 1111); and continuous seizure freedom rates were 22.4% (n = 923), 15.7% (n = 1165), and 11.7% (n = 1111). During the whole study follow-up, 551/1639 (33.6%) patients discontinued BRV. TEAEs since prior visit were reported in 25.6% (n = 1542), 14.2% (n = 1376), and 9.3% (n = 1232) of patients at 3, 6, and 12 months, respectively. CONCLUSIONS: This pooled analysis using data from a variety of real-world settings suggests BRV is effective and well tolerated in routine clinical practice in a highly drug-resistant patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Refractory Epilepsy Unit, Hospital Universitario y Politécnico La Fe, EpiCARE member, Avenida Fernando Abril Martorell 106, 46026, Valencia, Spain. villanueva_vichab@gva.es.
- UCB Pharma, Brussels, Belgium.
- Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne, Melbourne, Australia.
- Emory Epilepsy Center, Atlanta, GA, USA.
- Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA.
- The University of Sheffield, Sheffield, UK.
ORCID-Profile: Vicente Villanueva, Wendyl D'Souza, Adam Strzelczyk, Jerzy P Szaflarski, Bernhard J Steinhoff
Förderung
- UCB Pharma
Zitieren
APA
Villanueva, V., Laloyaux, C., D'Souza, W., Faught, E., Klein, P., Reuber, M., Rosenow, F., Salas-Puig, J., Insuga, V. S., Strzelczyk, A., Szaflarski, J. P., Chinn, C., Daniels, T., Floricel, F., Friesen, D., Sendersky, V., Besson, H., & Steinhoff, B. J. (2023). Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records. CNS Drugs, 37(9), 819-835. https://doi.org/10.1007/s40263-023-01033-4
Vancouver
Villanueva V, Laloyaux C, D'Souza W, Faught E, Klein P, Reuber M, et al. Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records. CNS Drugs. 2023;37(9):819-835. doi:10.1007/s40263-023-01033-4
BibTeX
@article{Villanueva2023,
author = {Villanueva, Vicente and Laloyaux, Cédric and D'Souza, Wendyl and Faught, Edward and Klein, Pavel and Reuber, Markus and Rosenow, Felix and Salas-Puig, Javier and Insuga, Victor Soto and Strzelczyk, Adam and Szaflarski, Jerzy P and Chinn, Chris and Daniels, Tony and Floricel, Florin and Friesen, David and Sendersky, Veronica and Besson, Hervé and Steinhoff, Bernhard J},
title = {Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records},
journal = {CNS Drugs},
year = {2023},
volume = {37},
number = {9},
pages = {819--835},
doi = {10.1007/s40263-023-01033-4}
}
EUVIMED